Sensus Healthcare recently announced that it has received FDA market clearance for its Sculptura radiation oncology system.
The Sculptura is a robotic intraoperative radiation therapy system that uses the company’s Beam Sculpting technology to treat cancer during surgery.
“With the creation of Sculptura, Sensus is pioneering a new whole approach to radiation oncology that will ultimately benefit both patients and the medical community at large,” Joe Sardano, CEO of Sensus Healthcare, said in a press release. “This system has the potential to give surgeons and radiation oncologists at hospitals and cancer centers the ability to eliminate weeks of post-operative radiation treatments that patients have to undergo after surgery. It is a game-changer that will provide a significantly better quality of life for patients post-surgery.”
The first Sculptura system was installed at the University of Pennsylvania’s Perelman School of Medcine’s department of radiation oncology.
“Sensus will introduce Sculptura into the marketplace to help cancer patients all over the world have a more manageable and effective radiation oncology experience,” Sardano said. “Sculptura is a paradigm-shifting technology that will not only help doctors to uniquely sculpt exact areas of the body with the radiation beam, but also result in similar or better outcomes to current radiation treatments today, with much less collateral damage.”
As a single treatment during surgery, the Scupltura will give cancer patients and physicians a single radiation treatment at the point of surgery, according to the company.
“Sculptura has several exclusive features that make this robotically assisted therapy system vastly different from everything else that’s available to patients on the market today,” Kai Fishman, chief technology officer at Sensus Healthcare, said. “From its 3D Beam Sculpting and respiratory motion tracking to the embedded image guidance and treatment area illumination, Sculptura is a first-of-its-kind, best-in-class treatment for cancer patients everywhere that will considerably change the status quo and forever alter how we think about cancer therapy today.”
